Country’s largest pharmaceutical company, Ranbaxy Laboratories Limited, announced that it has acquired manufacturing facilities that have the approval from the U.S. Food and Drug Administration (FDA).

Speaking on this, Malvinder Singh, CEO Ranbaxy Laboratories said, “We will transfer (production of) some products from India to America. Also, we are looking at making some acquisitions of manufacturing assets.”

He added that apart from US, his company is also keeping its options open to buy FDA-approved facilities from other countries.

Recently, company’s quality control specifications were questioned by the US FDA. The Indian drug maker, however, denied all such allegations. It is also believed that Nippon Chemiphar Co., a Japanese drug maker, is in talks with Ranbaxy about possibly ending a venture that produces generic drugs in Japan.

Last year Japanese drugmaker Daiichi Sankyo took a 63.9 per cent stake in the Indian generic drug maker.

The Gurgaon based company produces a wide range of quality and affordable generic medicines. At present, Ranbaxy is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.